« Protagonist Therapeutics (Nasdaq: PTGX) announced today that the Division of Nonmalignant Hematology at the U.S. Food and Drug Administration ("FDA") has provided important feedback during an End-of-Phase 2 meeting on rusfertide (PTG-300), an investigational new treatment for polycythemia vera ("PV"). Protagonist has also received written comments from the European Medicines Agency ("EMA") supportive of the Company's pivotal clinical development plan in PV »
Protagonist Therapeutics to Initiate Global Phas... - MPN Voice
Protagonist Therapeutics to Initiate Global Phase 3 Study for Rusfertide in Polycythemia Vera Following Interactions with FDA and EMA
Written by
Manouche
To view profiles and participate in discussions please or .
Read more about...
2 Replies
•
Thank you for posting, there is hope...
Hi Manouche, , many Thanks for keeping us abreast of these latest developments. . It's good to know so much research is going on. Regards -Chris
Not what you're looking for?
You may also like...
FDA Rejects Ropeginterferon alfa-2b for Polycythemia Vera
can become available for patients with polycythemia vera, the FDA has requested additional...
Phase 3, Trial of Interferon-α versus Hydroxyurea in Polycythemia Vera and Essential Thrombocythemia
i/10.1182/blood.2021012743/483404/A-Randomized-Phase-3-Trial-of-Interferon-versus
Polycythemia Vera Management Often Does Not Follow Guidelines
thrombotic events »...
A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia
news.
“A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and...
BESREMI ACHIEVES PATIENT-SPECIFIC TREATMENT GOALS IN POLYCYTHEMIA VERA: FINAL RESULTS FROM THE PROUD-PV/CONTINUATION-PV STUDIES
Long-term Besremi therapy fulfils treatment goals important to patients with PV: a good quality of...